ConductScience.org, home

Paper42699720

Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India.

Dubey P and 2 others. Cureus, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India. Papers, record 42699720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42699720

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India.
PubMed
Journal
Cureus
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dubey PPiyush
2Gupta PParul
3Yadav MManav

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131548545Breast cancer.Nat Rev Dis Primers2019https://conductscience.org/library/papers/31548545PubMed
232673076Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.JCO Glob Oncol2020https://conductscience.org/library/papers/32673076PubMed
326364145Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.Clin Breast Cancer2016https://conductscience.org/library/papers/26364145PubMed
432164163Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.Cancers (Basel)2020https://conductscience.org/library/papers/32164163PubMed
524842267Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.Breast Cancer Res Treat2014https://conductscience.org/library/papers/24842267PubMed
624647569In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.Clin Cancer Res2014https://conductscience.org/library/papers/24647569PubMed
730524905Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.Oncoimmunology2018https://conductscience.org/library/papers/30524905PubMed
811135226COX-2 is expressed in human pulmonary, colonic, and mammary tumors.Cancer2000https://conductscience.org/library/papers/11135226PubMed
930201790Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.BMJ2018https://conductscience.org/library/papers/30201790PubMed
1028801156Alarming Burden of Triple-Negative Breast Cancer in India.Clin Breast Cancer2018https://conductscience.org/library/papers/28801156PubMed
1134097070PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.J Natl Cancer Inst2021https://conductscience.org/library/papers/34097070PubMed
1225669979Prognostic and predictive value of PDL1 expression in breast cancer.Oncotarget2015https://conductscience.org/library/papers/25669979PubMed
1329846104Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.Arch Pathol Lab Med2018https://conductscience.org/library/papers/29846104PubMed
1428079291Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.Breast J2017https://conductscience.org/library/papers/28079291PubMed
1535139274Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.N Engl J Med2022https://conductscience.org/library/papers/35139274PubMed
1633538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
1727184417Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Nat Rev Clin Oncol2016https://conductscience.org/library/papers/27184417PubMed
1810963602Molecular portraits of human breast tumours.Nature2000https://conductscience.org/library/papers/10963602PubMed
1920586616
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
Arch Pathol Lab Med2010https://conductscience.org/library/papers/20586616PubMed
2016611412The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.Neoplasia2006https://conductscience.org/library/papers/16611412PubMed

See all 30 referencesDownload CSV of references

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42699720

GET https://conductscience.org/api/papers/v1/42699720/references?page=2